Leukeran

Chlorambucil, the active ingredient in Leukeran, is an alkylating agent presented as an oral formulation for oral use. It is employed in the treatment of certain blood cancers, primarily chronic lymphocytic leukemia and non‑Hodgkin lymphoma, in adult patients. GNH USA supplies Leukeran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Leukeran (chlorambucil) is an alkylating antineoplastic used in hematologic malignancies. - Chronic lymphocytic leukemia: helps control disease progression and improve survival. - Non‑Hodgkin lymphoma: contributes to tumor reduction and remission in indolent subtypes. - Low‑grade B‑cell lymphomas: provides disease control where other therapies may be unsuitable.

Adverse reactions may occur with chlorambucil therapy.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional episodes after dosing. - Bone marrow suppression: reduced white cells, red cells, or platelets. - Alopecia: thinning or loss of hair. - Fatigue: generalized tiredness. - Diarrhea: loose stools, often transient.

Serious or Rare Side Effects: - Secondary malignancies: risk of new cancers developing later. - Severe neutropenia: markedly low neutrophil count, increasing infection risk. - Aplastic anemia: profound bone‑marrow failure. - Pulmonary fibrosis: scarring of lung tissue, causing breathing difficulty. - Severe allergic reactions: rash, swelling, or anaphylaxis.

Patients receiving chlorambucil should be monitored closely for safety concerns. - Monitor blood counts: regular CBC to detect marrow suppression. - Assess renal function: adjust use if kidney impairment is present. - Evaluate liver function: check enzymes before and during therapy. - Avoid in hypersensitivity: discontinue if allergic reaction occurs. - Use contraception: prevent pregnancy during treatment and for a defined period after. - Store at ambient temperature: keep in the original pack, protect from moisture.

Chlorambucil may interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Warfarin: increased bleeding risk. - Live vaccines: reduced efficacy and possible infection. - Other alkylating agents: additive bone‑marrow toxicity. - Azathioprine: heightened immunosuppression. - Myelosuppressive antibiotics: compounded hematologic effects.

Moderate Interactions (Monitor Closely): - NSAIDs: may aggravate gastrointestinal irritation. - Allopurinol: potential increase in chlorambucil levels. - ACE inhibitors: monitor blood pressure and renal function. - Anticonvulsants: possible alteration of drug metabolism. - Oral contraceptives: reduced effectiveness, consider alternative methods.